Amarin Corp. PLC (AMRN) Stock Price Up 3.1%
Amarin Corp. PLC (NASDAQ:AMRN) rose 3.1% during trading on Tuesday . The stock traded as high as $3.30 and last traded at $3.29, with a volume of 1,015,046 shares changing hands. The stock had previously closed at $3.19.
AMRN has been the subject of several recent analyst reports. Zacks Investment Research raised shares of Amarin Corp. PLC from a “hold” rating to a “buy” rating and set a $3.75 target price for the company in a research note on Thursday, August 4th. Jefferies Group reissued a “buy” rating and set a $3.50 price objective on shares of Amarin Corp. PLC in a research report on Thursday, July 7th. Finally, HC Wainwright reissued a “buy” rating and set a $10.00 price objective on shares of Amarin Corp. PLC in a research report on Monday.
The stock has a 50 day moving average of $2.47 and a 200 day moving average of $1.87. The company’s market capitalization is $612.71 million.
Amarin Corp. PLC (NASDAQ:AMRN) last posted its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.13) by $0.06. During the same quarter in the prior year, the business earned ($0.15) earnings per share. The business had revenue of $32.82 million for the quarter, compared to analyst estimates of $29.97 million. The firm’s quarterly revenue was up 85.4% on a year-over-year basis. On average, analysts expect that Amarin Corp. PLC will post ($0.53) EPS for the current fiscal year.
Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company’s lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.